Ceska gynekologie · 2004
[New options in pharmacological treatment of urinary stress incontinence in women].
Аннотация на английскомСтатьяПоддержка исследования: вне правительства СШАОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martan A
Аннотация
OBJECTIVE: The aim of this paper is to provide a brief update review of current pharmacological agents used to treat women with GSI (Genuine Stress Incontinence).
DESIGN: Review article.
SETTING: Gynecological and Obstetric Clinic, 1. LF UK and VFN, Apolinárskã 18, Prague 2.
RESULTS: Genuine stress urinary incontinence is the involuntary loss of urine associated with increasing of intraabdominal pressure (such as running, jumping, coughing, etc.). Although the pelvic floor muscle training, behavioral and surgical therapies are currently the mainstay of treating GSI, we believe that pharmacological treatment can help to increase the cure rate. With the advent of duloxetine, a serotonin (5-hydroxytryptamine [5-HT]) and norepinephrine (NE) reuptake inhibitor acting within the sacral spinal cord, the role of pharmacological treatment of GSI must be reviewed ev. re-examined.
DESIGN: Review article.
SETTING: Gynecological and Obstetric Clinic, 1. LF UK and VFN, Apolinárskã 18, Prague 2.
RESULTS: Genuine stress urinary incontinence is the involuntary loss of urine associated with increasing of intraabdominal pressure (such as running, jumping, coughing, etc.). Although the pelvic floor muscle training, behavioral and surgical therapies are currently the mainstay of treating GSI, we believe that pharmacological treatment can help to increase the cure rate. With the advent of duloxetine, a serotonin (5-hydroxytryptamine [5-HT]) and norepinephrine (NE) reuptake inhibitor acting within the sacral spinal cord, the role of pharmacological treatment of GSI must be reviewed ev. re-examined.